A practical reference on adipose tissue: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-24 and is reviewed periodically as new material appears.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
The RSAF's overseas detachments in the United States are: Luke Air Force Base in Arizona, Marana in Arizona, Mountain Home Air Force Base in Idaho, and Andersen Air Force Base in Guam. The SAF has sent forces to assist in operations outside the country, in areas such as Iraq, and Afghanistan, in both military and civilian roles. In the region, they have helped to stabilise East Timor and have provided aid to Aceh in Indonesia following the 2004 Indian Ocean earthquake and tsunami. Since 2009, the Republic of Singapore Navy (RSN) has deployed ships to the Gulf of Aden to aid in countering piracy efforts as part of Task Force 151. The SAF also helped in relief efforts during Hurricane Katrina, and Typhoon Haiyan. Singapore is part of the Five Power Defence Arrangements (FPDA), a military alliance with Australia, Malaysia, New Zealand, and the United Kingdom. According to the 2024 Global Peace Index, Singapore is the 5th most peaceful country in the world.
== Interactions == Drug interactions with drotrecogin have not been systematically studied in patients with severe sepsis. Caution should be exercised when using other drugs that affect hemostasis concomitantly with drotrecogin (e.g. aspirin, warfarin, clopidogrel). However, the use of low dose prophylactic Heparin did not affect safety when given concurrently with drotrecogin.
Pfizer has hired customs and narcotics experts worldwide to track down fakes and assemble evidence that can be used to pursue civil suits for trademark infringement. In July 2008, Pfizer announced 275 job cuts at its manufacturing facility in Portage, Michigan. Portage was previously the world headquarters of Upjohn Company, which had been acquired as part of Pharmacia.
=== China === In July 2007, officials of the People's Republic of China seized US-produced pork for containing ractopamine residues. Further shipments of Canadian ractopamine-fed pork were seized in September 2007. In June 2019, customs inspectors in China detected ractopamine in a shipment of Canadian pork products destined for Chinese consumption. The Chinese government thereupon suspended not only pork, but also beef imports from Canada. Canadian Agriculture Minister Marie-Claude Bibeau stated that the CRFPCP certificate was a forgery and called in the RCMP, while Canadian Public Safety Minister Ralph Goodale stressed that the federal government would vigorously defend Canadian meat producers. It was also revealed that the Canadian Cattlemen's Association said in a statement that "We are fully confident in our meat production systems in Canada and the safeguards we have in place." Meanwhile, holes were found in the CRFPCP programme because the meat packer at the centre of the controversy was a chilled butcher shop only.<what> It was disclosed on 3 July that the Chinese authorities had discovered 188 falsified CRFPCP certificates.
==== Works ==== A.A.A (EP), by Nigerian band A.A.A AAA (Lee Hwi-min album), 2022 AAA (Hyukoh and Sunset Rollercoaster album), 2024 Access All Areas (EP), by The AAA Girls, 2017 Access All Areas (Flo album), 2024, including a song titled "AAA" "AAA", a song on City (Strapping Young Lad album), 1997 "Aaa", a song by They Might Be Giants on their 2015 album Glean Greek: "ΑΑΑ (ΑΑΑ) και χωρίσαμε", romanized: AAA (AAA) kai korisame, lit. 'AAA (AAA) and we broke up', a song on Kravgi by Anna Vissi, 2000
Sources: en.wikipedia.org
The conservation of energy is a common feature in many physical theories. From a mathematical point of view it is understood as a consequence of Noether's theorem, developed by Emmy Noether in 1915 and first published in 1918. In any physical theory that obeys the stationary-action principle, the theorem states that every continuous symmetry has an associated conserved quantity; if the theory's symmetry is time invariance, then the conserved quantity is called "energy". The energy conservation law is a consequence of the shift symmetry of time; energy conservation is implied by the empirical fact that the laws of physics do not change with time itself. Philosophically this can be stated as "nothing depends on time per se". In other words, if the physical system is invariant under the continuous symmetry of time translation, then its energy (which is the canonical conjugate quantity to time) is conserved. Conversely, systems that are not invariant under shifts in time (e.g. systems with time-dependent potential energy) do not exhibit conservation of energy – unless we consider them to exchange energy with another, external system so that the theory of the enlarged system becomes time-invariant again. Conservation of energy for finite systems is valid in physical theories such as special relativity and quantum theory (including QED) in the flat space-time.
==== TCR β-chain selection ==== At the DN2 stage (CD44+CD25+), cells upregulate the recombination genes RAG1 and RAG2 and re-arrange the TCRβ locus, combining V-D-J recombination and constant region genes in an attempt to create a functional TCRβ chain. As the developing thymocyte progresses through to the DN3 stage (CD44−CD25+), the thymocyte expresses an invariant α-chain called pre-Tα alongside the TCRβ gene. If the rearranged β-chain successfully pairs with the invariant α-chain, signals are produced which cease rearrangement of the β-chain (and silence the alternate allele). Although these signals require the pre-TCR at the cell surface, they are independent of ligand binding to the pre-TCR. If the chains successfully pair a pre-TCR forms, and the cell downregulates CD25 and is termed a DN4 cell (CD25−CD44−). These cells then undergo a round of proliferation, and begin to re-arrange the TCRα locus during the double-positive stage.
Jung decided that his near-psychotic experiences were of value and, in private, he induced hallucinations or, in his words, a process of "active imagination". He recorded everything he experienced in small journals, which Jung referred to in the singular as his Black Book, considering it a "single integral whole", even though some of these original journals have a brown cover. Jung described his 1912 book as "an attempt, only partially successful, to create a wider setting for medical psychology and to bring the whole of the psychic phenomena within its purview". The book was later revised and retitled Symbols of Transformation in 1952. The material Jung wrote was subjected to several edits, hand-written and typed, including another, "second layer" of text, his continual psychological interpretations during the process of editing. Around 1915, Jung commissioned a large red leather-bound book, and began to transcribe his notes and paint, working intermittently for sixteen years. Jung left no posthumous instructions about the final disposition of what he called the Liber Novus or Red Book. Sonu Shamdasani, a historian of psychology from London, tried for three years to persuade Jung's resistant heirs to have it published. Ulrich Hoerni, Jung's grandson who manages the Jung archives, decided to publish it when the necessary additional funds were raised through the Philemon Foundation. Up to September 2008, fewer than about two dozen people had ever seen it. In 2007, two technicians for DigitalFusion, working with New York City publishers W. W.
ferredoxin–nicotinamide adenine dinucleotide reductase ferredoxin reductase NAD+-ferredoxin reductase ferredoxin–NAD+ reductase ferredoxin–linked NAD+ reductase ferredoxin–NAD reductase When NAD molecule is in its reduced form, the enzyme is referred to as:
Sources: en.wikipedia.org
Humans do not produce cellulases, chitinases, or trehalases, but the bacteria in the gut microbiota do. In order to get into or out of cell membranes of cells and membranes of cell compartments, glucose requires special transport proteins from the major facilitator superfamily. In the small intestine (more precisely, in the jejunum), glucose is taken up into the intestinal epithelium with the help of glucose transporters via a secondary active transport mechanism called sodium ion-glucose symport via sodium/glucose cotransporter 1 (SGLT1). Further transfer occurs on the basolateral side of the intestinal epithelial cells via the glucose transporter GLUT2, as well uptake into liver cells, kidney cells, cells of the islets of Langerhans, neurons, astrocytes, and tanycytes. Glucose enters the liver via the portal vein and is stored there as a cellular glycogen. In the liver cell, it is phosphorylated by glucokinase at position 6 to form glucose 6-phosphate, which cannot leave the cell. Glucose 6-phosphatase can convert glucose 6-phosphate back into glucose exclusively in the liver, so the body can maintain a sufficient blood glucose concentration. In other cells, uptake happens by passive transport through one of the 14 GLUT proteins. In the other cell types, phosphorylation occurs through a hexokinase, whereupon glucose can no longer diffuse out of the cell. The glucose transporter GLUT1 is produced by most cell types and is of particular importance for nerve cells and pancreatic β-cells. GLUT3 is highly expressed in nerve cells.
The association of bacterial species with the production of the toxin is unequivocal – Lago and coworkers state, "[e]ndocellular symbiotic bacteria have been proposed as a possible source of eukaryotic TTX by means of an exogenous pathway", and Chau and coworkers note that the "widespread occurrence of TTX in phylogenetically distinct organisms... strongly suggests that symbiotic bacteria play a role in TTX biosynthesis" – although the correlation has been extended to most but not all animals in which the toxin has been identified. To the contrary, there has been a failure in a single case, that of newts (Taricha granulosa), to detect TTX-producing bacteria in the tissues with highest toxin levels (skin, ovaries, muscle), using PCR methods, although technical concerns about the approach have been raised. Critically for the general argument, Takifugu rubripes puffers captured and raised in laboratory on controlled, TTX-free diets "lose toxicity over time", while cultured, TTX-free Takifugu niphobles puffers fed on TTX-containing diets saw TTX in the livers of the fishes increase to toxic levels. Hence, as bacterial species that produce TTX are broadly present in aquatic sediments, a strong case is made for ingestion of TTX and/or TTX-producing bacteria, with accumulation and possible subsequent colonization and production.
=== 23 October === A third drone attack was carried out on Khartoum International Airport. Five people were killed in a drone strike on a market in El Fasher. The Central Bank of Sudan froze the assets of former prime minister Abdalla Hamdok and 38 other politicians on charges of supporting the RSF.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.